ASPI

ASPI (ASP Isotopes Inc.) Analyst Note Date: 2026-06-13 Current Price: $7.18

1. Structural Readiness

• Current Price: $7.18
• Extension: —
• ATR Context: Current ATR is 9.6% (Extreme). This indicates severe volatility and elevated risk for position sizing, consistent with a pre-commercialization stage in a capital-intensive sector.

2. Thesis Layer

As of 2026-06-13, ASPI is classified as a TACTICAL, setup-led name. There is no named secular thesis attached to this specific setup at this date. The investment case must be judged strictly on the quality of the technical setup (the forming coil) and the immediate business fundamentals (commercialization progress), rather than a broad macro narrative. We do not invent a thesis; we evaluate the company on its ability to execute its stated operational milestones.

3. Business Overview

ASP Isotopes Inc. operates in the Materials sector, specifically within the Isotope Enrichment industry. The company utilizes its proprietary ASP technology to enrich critical isotopes for nuclear medicine, semiconductors, and nuclear energy.

Operational Status & Milestones (as of 2026-06-13):

• Carbon-14 (C-14): The company resolved a feedstock issue in early 2025. As of the April 2025 earnings call, the plant was enriching C-14. Management holds a "take or pay" contract for a minimum of $2.5 million annually.
• *Target:* Initial commercial shipments were targeted for mid-2026 (per April 2026 filing) or Q3 2026 (per May 2026 filing). As of June 2026, the company is in the immediate window of these targets.
• Silicon-28 (Si-28): Used for advanced semiconductors and quantum computing.
• *Target:* Initial commercial shipments targeted for mid-2026 (April 2026 filing) or Q2 2026 (May 2026 filing).
• *Customers:* Purchase orders exist with a US semiconductor company and a global industrial gas company (entered April/June 2024).
• Ytterbium-176 (Yb-176): Used for medical applications.
• *Target:* Initial commercial shipments targeted for mid-2026 or Q3 2026.
• *Pricing:* Management cited a potential price of $20,000 per gram with a production capacity of 1 kilogram per year.
• Uranium Enrichment (HALEU):
• *Partnership:* A term sheet with TerraPower (Oct 2024) and a Loan Agreement (May 2025) for $22.0 million to fund a HALEU facility in South Africa.
• *Offtake:* A 10-year supply agreement for up to 150 metric tons of HALEU, commencing in 2028.
• Financial Position: Management expressed an expectation to reach cash flow breakeven or better in the second half of 2026 (April 2025 call). Forward consensus EPS for FY1 and FY2 remains negative (-1.14 and -1.16 respectively), indicating the company is still in a pre-profitability growth phase.

4. Archetype and Conviction

• Archetype: Deep Value Recovery (with strong Growth Leader characteristics).
• *Rationale:* The company is transitioning from a development stage to commercial production. The "Deep Value" aspect is derived from the potential for a significant rerating as the company moves from negative EPS to cash flow breakeven, supported by secured offtake agreements (TerraPower, C-14 customer).
• Conviction Stack:
• Thesis Strength: Moderate. The business model is clear, but the "no named secular thesis" constraint limits the macro tailwind argument.
• Evidence Quality: High. Multiple primary sources (earnings calls, SEC filings) confirm specific milestones, pricing, and customer contracts.
• Structural Quality: The forming coil suggests accumulation, but the Extreme ATR (9.6%) is a significant negative factor. Historically, extreme ATR (>8%) correlates with a higher rate of severe losers, suggesting the setup is fragile and requires tight risk management.
• Rerating Potential: High, contingent on the successful execution of the Q2/Q3 2026 shipment targets.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen the Case:
• Confirmation of initial commercial shipments for C-14, Si-28, or Yb-176 in Q2 or Q3 2026.
• Announcement of additional customer orders or expansion of existing order sizes (as hinted in April 2025).
• Achievement of cash flow breakeven in H2 2026.
• What Would Invalidate the Case:
• Delay in commercial shipments beyond the Q3 2026 window without a credible explanation.
• Failure to secure the HALEU facility funding or termination of the TerraPower agreement.
• Gaps in Evidence:
• Revenue Recognition: While targets are set, there is no evidence of *actual* revenue booked from these shipments as of June 13, 2026. The "take or pay" contract is a floor, not a realized top-line driver yet.
• Margin Data: No specific gross margin data is available for the new products; the $20,000/gram price for Yb-176 is a target, not a realized margin.
• Cash Burn: While breakeven is targeted, the exact cash burn rate leading up to H2 2026 is not detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key evidence: Secured offtake agreements (TerraPower, C-14 take-or-pay); Specific commercial shipment targets for mid-2026/Q3 2026; Management guidance for cash flow breakeven in H2 2026. Key risks: Extreme volatility (9.6% ATR) indicating high risk of severe drawdown; Pre-revenue status with negative consensus EPS; Execution risk on complex enrichment facility construction and feedstock logistics. Sizing hint: Position size must be minimal due to extreme ATR and pre-commercialization status; treat as a high-risk optionality play. Expected path: Price consolidates in a forming coil structure while management executes on Q2/Q3 shipment targets; potential breakout if shipments are confirmed and breakeven guidance is met. Expected horizon: 3 to 6 months (until H2 2026 breakeven confirmation or shipment delivery).